ライフサイエンスコーパス: adrenoceptor

1 ceptor (1000-fold selectivity over the beta1-adrenoceptor).

2 SAT and very little expression of the beta3-adrenoceptor.

3 protein-coupled receptors such as the beta2-adrenoceptor.

4 e antagonists/inverse agonists of the alpha2-adrenoceptor.

5 does not occur in the closely related beta2-adrenoceptor.

6 of such shape-shifting system as the beta(2)-adrenoceptor.

7 angiotensin II type 1 receptor and the beta2 adrenoceptor.

8 to contain the highest densities of alpha2C adrenoceptors.

9 lamus, regions with low densities of alpha2C adrenoceptors.

10 otracer for in vivo imaging of brain alpha2C adrenoceptors.

11 macrophages, which was independent of alpha1 adrenoceptors.

12 cules that could bias signalling in the beta-adrenoceptors.

13 D -8.95) and is very selective for the beta2-adrenoceptor (1000-fold selectivity over the beta1-adren

14 e other two subtypes difficult and the beta3-adrenoceptor a less-understood subtype.

15 onflicting functional activity at the alpha2-adrenoceptor, a G-protein-coupled receptor with relevanc

16 s) to directly probe activation of the beta2-adrenoceptor, a prototypical GPCR, and its cognate G pro

17 eart disease and heart attack) and many beta-adrenoceptor acting drugs are listed on the WHO Model Li

18 son's disease as a result of the use of beta-adrenoceptor-acting drugs in different populations.

19 we decipher the ascending circuitry linking adrenoceptor-activated sacral CPGs and lumbar flexor mot

20 e chronotropic effect on top of maximal beta-adrenoceptor activation in healthy mice.

21 e chronotropic effect on top of maximal beta-adrenoceptor activation in healthy mice.

22 e the autophagy effect of sustained beta(2) -adrenoceptor activation in rodents with neurogenic myopa

23 dy investigated the hypothesis that alpha(2)-adrenoceptor activation inhibits icilin-induced WDS.

24 abolishes the beneficial effects of beta(2) -adrenoceptor activation on the skeletal muscle proteosta

25 Sustained beta(2) -adrenoceptor activation using Formoterol (10 mug kg(-1)

26 Instead, beta2 adrenoceptor activation was responsible for mediating ge

27 pporting an autophagy mechanism for beta(2) -adrenoceptor activation, skeletal muscle-specific deleti

28 so found that antagonism of hippocampal beta-adrenoceptor activity with local infusions of propranolo

29 ion variant of the gene encoding the alpha2b-adrenoceptor (ADRA2B), which has been linked to emotiona

30 ietary sodium affects function of the beta-2 adrenoceptor (ADRB2).

31 epatic progenitor/oval cells (HPCs) and beta-adrenoceptor agonism will expand HPCs to reduce AILI.

32 isk of Parkinson's disease with chronic beta-adrenoceptor agonist (eg, salbutamol) use, and by functi

33 ed corticosteroid (ICS)/long-acting beta (2)-adrenoceptor agonist (LABA) combination therapy should b

34 al cells, formoterol, a long-acting beta (2)-adrenoceptor agonist (LABA), enhanced the expression of

35 ill inevitably be taking a long-acting beta2-adrenoceptor agonist (LABA)/ICS combination therapy, we

36 Overuse of beta2-adrenoceptor agonist bronchodilators evokes receptor des

37 e have further characterized the novel beta2 adrenoceptor agonist C26 (7-[(R)-2-((1R,2R)-2-benzyloxyc

38 y intra-BAT injections of the specific beta3-adrenoceptor agonist CL316,243 in one pad and the vehicl

39 xidase (MAO) inhibitor harmane, the alpha(2)-adrenoceptor agonist clonidine, the mu-opioid receptor a

40 nd coronary perfusion during CPR via alpha-1-adrenoceptor agonist effects.

41 Starting from the beta-adrenoceptor agonist isoprenaline and beta-blocker carve

42 ed using multiple concentrations of the beta-adrenoceptor agonist isoproterenol (ISO) and by varying

43 to tachyphylaxis and would thus avoid beta2-adrenoceptor agonist resistance.

44 ociation rate we have observed for any beta2 adrenoceptor agonist tested to date.

45 after 2 min of phenylephrine (PE; an alpha1 -adrenoceptor agonist) infusion via brachial artery cathe

46 erial infusion of phenylephrine (PE; alpha1 -adrenoceptor agonist) were calculated during (1) infusio

47 e dexmedetomidine, a highly selective alpha2 adrenoceptor agonist, could safely decrease the incidenc

48 d with APAP (350 mg/kg) followed by the beta-adrenoceptor agonist, isoproterenol (ISO), or the beta-a

49 Cold- and beta3-adrenoceptor agonist-induced sympathetic activation lead

50 combinations (with the Y4 receptor or beta2-adrenoceptor), agonist and antagonist pharmacology was e

51 ulmonary disease, which is treated with beta-adrenoceptor-agonist medications.

52 significantly enhanced by long-acting beta2-adrenoceptor agonists (LABAs) and may contribute to the

53 changes produced by the long-acting beta (2)-adrenoceptor agonists (LABAs) salmeterol, indacaterol, a

54 inetics of several clinically relevant beta2-adrenoceptor agonists and antagonists and demonstrated t

55 am cAMP/PKA signaling attenuated, while beta-adrenoceptor agonists and cAMP/PKA activators enhanced,

56 s that are currently available such as beta2-adrenoceptor agonists and corticosteroids, it takes litt

57 PD therapy involving anticholinergics, beta2-adrenoceptor agonists and/or corticosteroids, do not spe

58 Muscarinic receptor antagonists and beta-adrenoceptor agonists are used in the treatment of obstr

59 The beta2 adrenoceptor agonists formoterol and salbutamol mediated

60 n the neonatal exposure model, whereas beta2-adrenoceptor agonists had no such effect.

61 beta3-Adrenoceptor agonists have recently been introduced for

62 beta(2) -adrenoceptor agonists improve autophagy and re-establish

63 cal trial study show the efficacy of alpha-2 adrenoceptor agonists in decreasing stress-induced drug

64 of novel, potent, and selective human beta2 adrenoceptor agonists incorporating a sulfone moiety on

65 on's disease seen in patients receiving beta-adrenoceptor agonists is likely to be indirectly mediate

66 atecholamine surrogates present in the beta2-adrenoceptor agonists procaterol and BI-167107 (4), we d

67 s disease, while the chronic use of the beta-adrenoceptor agonists was associated with a decreased ri

68 mically and pharmacodynamically diverse beta-adrenoceptor agonists, isoproterenol and salmeterol.

69 of muscarinic receptor antagonists and beta-adrenoceptor agonists, the full value of such combinatio

70 Recent progress in structural data of beta-adrenoceptors allows us to understand and predict key in

71 but no more than single knockout of alpha1A-adrenoceptors alone.

72 nd serotonin (5-HT) receptors, we found that adrenoceptor alpha 2C (Adra2c) and serotonin receptor 2a

73 cific heteromerization between the alpha(1A)-adrenoceptor (alpha(1A)AR) and CXC chemokine receptor 2

74 crystal structure, we modeled the alpha(1B)-adrenoceptor (alpha(1B)-AR) to help identify the alloste

75 of prolonged stimulation of MOR on alpha(2)-adrenoceptor (alpha(2)-AR) function.

76 vity, which are genetically deficient in the adrenoceptor alpha2A and alpha2C genes (ARDKO).

77 e actions of noradrenaline at spinal alpha2 -adrenoceptors, although serotonin, acting on facilitator

78 Activation of the beta2-adrenoceptor and cannabinoid CB2 receptors can inhibit s

79 High levels of noradrenergic alpha1-adrenoceptor and dopaminergic D1 receptor stimulation ac

80 Both alpha1-adrenoceptor and mineralocorticoid receptor expressions

81 discovered much later than beta1- and beta2-adrenoceptors and exhibits unique properties which make

82 ed with altered signal transduction via beta-adrenoceptors and G proteins and with reduced cAMP forma

83 osteric inhibitor pharmacophore for alpha(1)-adrenoceptors and mechanistic insight and a new set of s

84 iction or on activation of alpha1- and beta1-adrenoceptors and miR-212/132 led to repression of MeCP2

85 uperoxide production that stimulates alpha2C-adrenoceptors and Rho-kinase-mediated MLC phosphorylatio

86 ha1A-adrenergic G protein-coupled receptors (adrenoceptors) and P2X1-purinoceptor ligand gated ion ch

87 nd beta1-adrenoceptors, chimeric beta2/beta1-adrenoceptors, and receptors with single-point mutations

88 Since intrathecal injection of an alpha(2A)-adrenoceptor antagonist (BRL 44408) partially reversed t

89 The beta1-adrenoceptor antagonist 1-[2-((3-Carbamoyl-4-hydroxy)phe

90 rdia and PVCs were abolished by the beta(1) -adrenoceptor antagonist atenolol.

91 ntagonist propranolol, the mixed alpha-/beta-adrenoceptor antagonist labetalol, and the alpha1-adreno

92 oceptor antagonist labetalol, and the alpha1-adrenoceptor antagonist prazosin.

93 d a link between the chronic use of the beta-adrenoceptor antagonist propranolol and an increased ris

94 that the administration of the beta1-, beta2-adrenoceptor antagonist propranolol decreases cardiac wo

95 mia was significantly attenuated by the beta-adrenoceptor antagonist propranolol, the mixed alpha-/be

96 The alpha(1) adrenoceptor antagonist WB4101, alpha(2) adrenoceptor an

97 eted for hypertension as a nonselective beta-adrenoceptor antagonist with alpha(1)AR antagonist prope

98 (1) adrenoceptor antagonist WB4101, alpha(2) adrenoceptor antagonist yohimbine and mu-opioid receptor

99 were administered hydrocortisone, the alpha2-adrenoceptor antagonist yohimbine, or both before they w

100 athecal administration of yohimbine (alpha-2-adrenoceptor antagonist).

101 luated LK 204-545 (1), (1) a selective beta1-adrenoceptor antagonist, and discovered it possessed sig

102 Prazosin, a potent and selective alpha1-adrenoceptor antagonist, displaces 25% of (11)C-CUMI-101

103 ted that (11)C-yohimbine, a selective alpha2-adrenoceptor antagonist, is an appropriate ligand for PE

104 or agonist, isoproterenol (ISO), or the beta-adrenoceptor antagonist, propranolol.

105 rats pretreated with atipamezole, an alpha2 adrenoceptor antagonist.

106 ere significantly reduced by alpha- and beta-adrenoceptor antagonists (-40%, p < 0.001 and -30%, p <

107 ulation of astrocytes was inhibited by alpha-adrenoceptor antagonists and abolished by depletion of n

108 r a causal relationship between use of beta2-adrenoceptor antagonists and the increased risk of Parki

109 beta-adrenoceptor antagonists are used by billions of patient

110 beta-Adrenoceptor antagonists boast a 50-year use for symptom

111 Novel selective beta1-adrenoceptor antagonists for concomitant cardiovascular

112 Even if causal, the effect of beta-adrenoceptor antagonists on the risk of Parkinson's dise

113 Adrenoceptor antagonists or vehicle (5 ml/kg saline) was

114 of Parkinson's disease associated with beta-adrenoceptor antagonists use can be explained by reverse

115 risk of Parkinson's disease because of beta-adrenoceptor antagonists use corresponds to one case in

116 Thus, not using beta-adrenoceptor antagonists would severely harm patients wi

117 , cimaterol) are potently inhibited by beta1-adrenoceptor antagonists, and 2) a low-affinity secondar

118 relatively resistant to inhibition by beta1-adrenoceptor antagonists.

119 ns containing oxymetazoline (OXY), an alpha1-adrenoceptor (AR) agonist of the imidazoline class.

120 have poor selectivity for the cardiac beta1-adrenoceptor (AR) over the lung beta2-AR.

121 sents approximately 25% of the total beta(2)-adrenoceptor (AR) population as determined with the anta

122 n the airways, muscarinic receptors and beta-adrenoceptors are expressed in different locations, indi

123 Adenosine receptors and beta-adrenoceptors are G-protein-coupled receptors (GPCRs) th

124 Muscarinic receptors and beta-adrenoceptors are physiological antagonists for smooth m

125 beta-adrenoceptors are widely expressed in different human or

126 Transcriptome data revealed alpha1 adrenoceptors (ARs) expression in platelet-derived growt

127 uture studies to better understand the beta3-adrenoceptor as a novel pharmacological target.

128 fied transmembrane region (TM)4 of the beta1-adrenoceptor as key for this low-affinity conformation.

129 Green Fluorescent Protein (GFP)-taggedbeta2 adrenoceptor at a slow rate, with half-life (t1/2) value

130 Thus, unlike at the human beta1-wild-type adrenoceptor, at beta1-TM4 mutant receptors, cimaterol a

131 four active-state structures of the beta(1)-adrenoceptor (beta(1)AR) bound to conformation-specific

132 The beta(1)-adrenoceptor (beta(1)AR) is a G-protein-coupled receptor

133 the architecture of agonist-occupied beta(2)-adrenoceptor (beta(2)AR) in complex with the heterotrime

134 NHERF1 is crucial to beta-2-adrenoceptor (beta(2)AR)-mediated activation of cystic f

135 es using knock-out mice suggest that beta(3)-adrenoceptor (beta(3)-AR) signaling is dependent on cave

136 ctivity (SNA) coupled with dysregulated beta-adrenoceptor (beta-AR) signaling is postulated as a majo

137 a condition characterized by excessive beta-adrenoceptor (beta-AR) stimulation.

138 udy, we examined the impact of AnxA4 on beta-adrenoceptor (beta-AR)/cAMP-dependent signal transductio

139 beta(2)-Adrenoceptors (beta(2)-AR) are prototypical G-protein-co

140 Cardiomyocyte beta(3)-adrenoceptors (beta(3)-ARs) coupled to soluble guanylyl

141 adiols mediate P-UAEC proliferation via beta-adrenoceptors (beta-AR) and independently of classic oes

142 ling by soluble stress hormones through beta-adrenoceptors (beta-AR) reduces the deformability of mac

143 ery endothelial cells (P-UAECs) through beta-adrenoceptors (beta-ARs) and independently of the classi

144 Anabolic beta2-adrenoceptor (beta2-AR) agonists have been proposed as t

145 beta2 adrenoceptor (beta2-AR)-agonists are used to relieve bro

146 sites into the C-terminal tail of the beta2-adrenoceptor (beta2AR) and demonstrate that this mutant,

147 Vps34 is required for recycling of the beta2-adrenoceptor (beta2AR), a prototypical GPCR, and then in

148 uch as adrenaline, which activates the beta2-adrenoceptor (beta2AR), bind with relatively low affinit

149 s simulations of lipid-embedded active beta2-adrenoceptor (beta2AR*) in complex with C-terminal pepti

150 acetylcholine receptors (mAChRs) and beta-2-adrenoceptors (beta2ARs) are important regulators of air

151 ld lower Na(+) concentrations, and the beta3 adrenoceptor (beta3 AR) mediates pump stimulation in myo

152 l studies suggest that stress activates beta-adrenoceptors (betaARs) to enhance metastasis from prima

153 llenges in designing and validating targeted adrenoceptor-binding radiotracers, namely the heavily we

154 It was found that under systemic beta-adrenoceptor blockade (atenolol) combined with spinal co

155 All trials occurred after local beta-adrenoceptor blockade (propranolol).

156 were performed during local alpha- and beta-adrenoceptor blockade (via a brachial artery catheter) t

157 Under beta-adrenoceptor blockade combined with spinal cord (C1) tra

158 mygdala (BLA) to examine the effects of beta-adrenoceptor blockade on immediate and delayed extinctio

159 beta-Adrenoceptor blockade with propranolol or inhibition of

160 We have shown that systemic beta-adrenoceptor blockade with propranolol rescues the IED,

161 pal D1/D5 receptor blockade and resistant to adrenoceptor blockade: memory enhancement and long-lasti

162 y of other combinations, for example, alpha1-adrenoceptor blocker and 5alpha-reductase inhibitor, has

163 patients with septic shock using the beta-1 adrenoceptor blocker, esmolol, with specific focus on sy

164 wn that both antimuscarinic drugs and alpha1-adrenoceptor blockers can be useful for treatment of mal

165 Here, we tested the efficacy of mixed adrenoceptor blockers carvedilol and labetalol, and the

166 , combinations of antimuscarinics and alpha1-adrenoceptor blockers have produced the most promising r

167 nhibitors seems to be as effective as alpha1-adrenoceptor blockers in male lower urinary tract sympto

168 ast years new formulations of several alpha1-adrenoceptor blockers were introduced to the market.

169 compounds exert their effects at the alpha2-adrenoceptor both in vitro in human prefrontal cortex ti

170 reducing salmeterol's affinity for the beta2-adrenoceptor by 31-fold.

171 fter activation of adipocyte-expressed beta3 adrenoceptors by catecholamines, and identified eosinoph

172 NDPK-C is a novel critical regulator of beta-adrenoceptor/cAMP signaling and cardiac contractility.

173 ll death, which is under the control of beta-adrenoceptor/cAMP/PKA axis through the regulation of PAR

174 aling and highlight the ability of the beta2-adrenoceptor/cAMP/PKA axis to rewire EphA2 signaling in

175 Prejunctional beta2-adrenoceptors can enhance neuronal acetylcholine release

176 synthesis and release of catecholamines, the adrenoceptors catecholamines bind to, and the cardiac an

177 rrently thought that activation of the beta2-adrenoceptor causes c-AMP dependent activation of PKA; h

178 At the beta1-adrenoceptor, CGP 12177 potently antagonizes agonist res

179 Wild-type beta2- and beta1-adrenoceptors, chimeric beta2/beta1-adrenoceptors, and r

180 affinity pharmacology of the secondary beta1-adrenoceptor conformation.

181 ole in the generation of the secondary beta1-adrenoceptor conformation.

182 rative interactions between 2 distinct beta1-adrenoceptor conformations.

183 anolol, respectively) and abolished in beta1-adrenoceptors containing TM4 mutations vital for the sec

184 with significant, regional-dependent alpha1 adrenoceptor cross-reactivity, limiting its potential us

185 showed that CUMI-101 had significant alpha1 adrenoceptor cross-reactivity.

186 nding techniques were used to measure alpha1-adrenoceptor density and the affinity of CUMI-101 for th

187 alpha1-adrenoceptor density and the affinity of CUMI-101 for th

188 Previously we reported on adrenoceptor-dependent sacral control of lumbar flexor m

189 reconstricted airways, irrespective of beta2-adrenoceptor desensitization.

190 rst, the ligand-recognition profile of beta3-adrenoceptors differs considerably from that of the othe

191 and parasympathetic nervous system, numerous adrenoceptor drugs were radiolabeled and potent radiolig

192 tween in vivo and in vitro measures of beta1-adrenoceptor efficacy (R(2)=0.93; P<0.0001).

193 Stimulation of alpha-adrenoceptors elicits vasoconstriction in resting skelet

194 The beta1-adrenoceptor exists in two agonist conformations/states:

195 P 12177 (BODIPY-TMR-CGP)] at the human beta1-adrenoceptor expressed in Chinese hamster ovary cells re

196 ity, associated with a restoration of alpha1-adrenoceptor expression in endotoxic shock.

197 sms of BDNF, muscarinic receptors, and beta3-adrenoceptor expression.

198 d both mineralocorticoid receptor and alpha1-adrenoceptor expressions within 5 hours in human vascula

199 e (TM) regions of the human beta1- and beta2-adrenoceptors, followed by single point mutations, to de

200 ontrast, arrestin-3 interaction with a beta2-adrenoceptor fused to the carboxyl-terminal tail of the

201 tional deletion polymorphism in the alpha-2B adrenoceptor gene (ADRA2B) has been linked to emotional

202 at the 16 position (rs1042713) in the beta2-adrenoceptor gene (ADRB2) is associated with enhanced do

203 The role of beta3-adrenoceptor gene polymorphisms has insufficiently been

204 ause they represent attractive drug targets, adrenoceptors have been widely studied.

205 Recent structures of beta-adrenoceptors highlight residues in transmembrane region

206 s that negative cooperativity across a beta1-adrenoceptor homodimer may be responsible for generating

207 ciation rate were markedly enhanced in beta1-adrenoceptor homodimers constrained by bimolecular fluor

208 the development of a PET tracer for alpha2C adrenoceptor imaging and its preliminary preclinical eva

209 L/6J mice, pharmacologic activation of beta2 adrenoceptors improved the severity of shock, including

210 ifying structural differences in the beta(1)-adrenoceptor in complex with beta-arrestin 1 versus a G

211 tic ganglia neurons and an increase of beta3-adrenoceptor in the SAT.

212 We show for the first time that adrenoceptors in anterior piriform cortex (aPC) must be

213 he maps of (11)C-yohimbine binding to alpha2 adrenoceptors in human brain had the highest values in c

214 he tracer (11)C-yohimbine for mapping alpha2 adrenoceptors in human brain in vivo.

215 mination of (11)C-CUMI-101 binding to alpha1-adrenoceptors in human cerebellum under in vivo conditio

216 egional differences in expression of alpha-1 adrenoceptors in human colon emphasize the translational

217 These results indicate that beta2-adrenoceptors in regulatory lymphocytes are critical for

218 alpha2C adrenoceptors in the human brain may be involved in vari

219 nhanced expression and sensitivity of alpha2-adrenoceptors in the LC.

220 from cells subjected to fractional, beta (2)-adrenoceptor inactivation determined that PDE4 inhibitio

221 rough the use of X-ray data from ligand-beta-adrenoceptor (including ADRB1 and ADRB2) crystal structu

222 )R with the agonist-bound structures of beta-adrenoceptors indicates that the contraction of the liga

223 most potent (20) and selective (vs the a(2-)adrenoceptor) inhibitors of hPNMT yet reported.

224 Acute stimulation of cardiac beta-adrenoceptors is crucial to increasing cardiac function

225 Second, the expression pattern of beta3-adrenoceptors is more restricted than that of other subt

226 nding in wild-type and alpha2A- and alpha2AC adrenoceptor knockout (KO) mice.

227 hese amino acids to those found in the beta2-adrenoceptor (L195Q and W199Y), or mutation of a single

228 Third, beta3-adrenoceptors lack the phosphorylation sites involved in

229 p between structural properties of the beta2-adrenoceptor ligands and their interactions with membran

230 signaling pathways induced by different beta-adrenoceptor ligands.

231 moderate affinity (Ki = 6.75 nM) for alpha1 adrenoceptors measured in vitro.

232 These findings suggest that beta-adrenoceptors mediate stress-induced changes in mPFC spi

233 sms, that is, direct catecholamine toxicity, adrenoceptor-mediated damage, epicardial and microvascul

234 otor nerves but induced sympathetic beta(1) -adrenoceptor-mediated dilatation.

235 of 5-HT neurons revealed that, while alpha1-adrenoceptor-mediated excitation was unchanged, excitato

236 sions, BAY reversed both the attenuated beta-adrenoceptor-mediated inotropy and chronotropy.

237 Muscarinic agonism may attenuate beta-adrenoceptor-mediated relaxation more than other contrac

238 hibition are critically involved in alpha(1)-adrenoceptor-mediated vascular smooth muscle contraction

239 senteric small arteries causes a large beta1-adrenoceptor-mediated vasodilatation, which contrasts wi

240 se cleavage-mediated) and reversible (alpha1 adrenoceptor-mediated) forms of channel activation.

241 nt of the ADRA2b gene coding for the alpha2b adrenoceptor modulates EEV in humans.

242 thers suggested that TM4 has a role in beta1-adrenoceptor oligomerization.

243 Importantly, the effect of beta3-adrenoceptor on mTOR complex 2 is independent of the cla

244 G7 blunts the beneficial effects of beta(2) -adrenoceptor on skeletal muscle proteostasis and contrac

245 lates the activity of agonist-occupied beta1-adrenoceptors on a very fast time scale.

246 ia their binding to the active site of beta2-adrenoceptors on ASM, which triggers a signaling cascade

247 alcium-cAMP signaling by stimulating alpha2A-adrenoceptors on spines strengthens synaptic efficacy an

248 no effect on signaling and function of beta2-adrenoceptor or numerous procontractile GPCRs, but selec

249 from Tpcn2(-/-) mice showing no loss of beta-adrenoceptors or coupling mechanisms.

250 his article discusses three aspects of beta3-adrenoceptor pharmacology.

251 Here we show that activation of beta2-adrenoceptors promoted STD long-term synaptic potentiati

252 agonism of the P2X1-purinoceptor and alpha1A-adrenoceptor provides a safe and effective therapeutic t

253 atic analysis, and the inability of targeted adrenoceptor radioligands to have an impact on clinical

254 Bronchodilators that do not target beta2-adrenoceptors represent a critical unmet need for asthma

255 ine the exact amino acids in the human beta2-adrenoceptor responsible for this very high selectivity.

256 rmine the key residues involved in the beta1-adrenoceptor secondary conformation.

257 odilatation, whereas 0.1 mum of the beta(2) -adrenoceptor selective antagonist ICI-118,551 had no eff

258 ile afforded 19, a ligand with similar beta1-adrenoceptor selectivity and partial agonism (log KD of

259 In vitro beta-adrenoceptor selectivity and partial agonism of 19 were

260 The alpha2C adrenoceptor selectivity of the tracer was determined by

261 This unique adrenoceptor selectivity profile likely accounts for the

262 pe mice selectively increased (40-60%) beta2-adrenoceptor signaling and function.

263 ampal synaptic plasticity by activating beta-adrenoceptor signaling and mitigating synaptotoxicity of

264 dent responses were mainly mediated by beta1-adrenoceptor signaling in TTS.

265 s a critical downstream effector of beta(2) -adrenoceptor signaling pathway in skeletal muscle.

266 tophagy as a downstream effector of beta(2) -adrenoceptor signaling pathway.

267 tion mediated via canonical beta1- and beta2-adrenoceptor signaling pathways; and (5) evidence for ad

268 ein LMBRD2 as a potential regulator of beta2 adrenoceptor signaling, underscoring the value of a dyna

269 We show that beta3-adrenoceptors stimulate glucose uptake in brown adipose

270 n (mTOR) complex 2 has a novel role in beta3-adrenoceptor-stimulated glucose uptake in brown adipose

271 Both parts are essential for beta3-adrenoceptor-stimulated glucose uptake.

272 Under submaximal beta-adrenoceptor stimulation of brown adipocytes, a PDE3 inh

273 Prolonged beta1-adrenoceptor stimulation suppresses IKs by downregulatin

274 antagonists are available for the human beta-adrenoceptor subtype involved in these diseases, yet few

275 a docking study at the alpha2A- and alpha2C-adrenoceptor subtypes demonstrating the structural featu

276 file at both 5-HT(1A) receptors and alpha(1)-adrenoceptor subtypes was measured by binding assay and

277 Structural modeling of the human beta1-adrenoceptor suggested interaction of the side chain of

278 human cerebellum reflects binding to alpha1-adrenoceptors, suggesting that the cerebellum is of limi

279 a hyperfunctional variant of the human beta1-adrenoceptor that carries an arginine at position 389 in

280 The pathway involves activation of beta2-adrenoceptors that increase cAMP levels and activate cAM

281 Desensitization of beta2-adrenoceptors that occurs during the first few days of r

282 , is an appropriate ligand for PET of alpha2 adrenoceptors that passes readily from blood to brain ti

283 neering phosphorylation sites into the beta2-adrenoceptor the receptor showed prolonged interaction w

284 a single residue (W199D) in the human beta1-adrenoceptor thus abolished this secondary conformation

285 centration response at human beta1-wild-type adrenoceptors to a monophasic concentration response in

286 pathways linking chronic stimulation of beta-adrenoceptors to hypertrophy and associated arrhythmias.

287 e observed with cardiomyocyte-specific beta1-adrenoceptor transgenic mice and human heart biopsies.

288 igated the effects of blocking 5-HT and beta-adrenoceptor transmission in DH on drug seeking during E

289 These findings indicate that alpha2-adrenoceptors trigger signals that protect the integrity

290 quantify the density and affinity of alpha 2 adrenoceptors under condition of changing radioligand bi

291 ificity of (11)C-ORM-13070 binding to alpha2 adrenoceptors was demonstrated in rats pretreated with a

292 The cross-reactivity of CUMI-101 with alpha1 adrenoceptors was performed using in vitro radioligand b

293 Their target, the beta3-adrenoceptor, was discovered much later than beta1- and

294 d mRNA levels of IGF-1, TGF-beta1, and beta3-adrenoceptor were increased at days 7 and/or 28.

295 so possess significant affinity for the a(2)-adrenoceptor, which complicates the interpretation of th

296 duction of in vitro affinity at the alpha(1)-adrenoceptor while both potency and efficacy were increa

297 h factor receptor (EGFR) with EGF, the beta2-adrenoceptor with dopamine, or the hepatocyte growth fac

298 s secondary conformation and created a beta1-adrenoceptor with only one high-affinity agonist conform

299 -fold, to within 4-fold of that of the beta1-adrenoceptor, without affecting the affinity or selectiv

300 y differs between the human and rodent beta3-adrenoceptor, yielding considerable species differences